Introduction
Watch an internationally renowned faculty discuss the optimization of CDK4/6 inhibitor treatment in patients with advanced breast cancer. Prof. Patrick Neven, Dr Shaneenah Dawood and Prof. Rupert Bartsch discuss treatment selection and sequencing, and future directions in the management of HR+/HER2– advanced breast cancer.
The information in this activity is intended for oncologists and other healthcare professionals involved in the treatment of patients with advanced breast cancer.
This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the International Consensus Conference for Advanced Breast Cancer 2019 (ABC5). The live voting content is no longer active for this symposium.
Learning objectives
After watching this touchSATELLITE SYMPOSIUM, you should be able to:
- Identify patient and disease characteristics that can inform treatment decisions in high-risk patients with HR+/HER2– ABC
- Translate clinical evidence and real-world data relating to HR+/HER2– ABC into daily practice
- Describe the practical considerations for maintaining adherence and improving patient outcomes through the management of the differing side effect profiles of the CDK4/6 inhibitors in patients with HR+/HER2– ABC